Philips Collaborates with Merck KGaA to Advance Personalized Fertility Treatment

Shots:

  • The companies have launched a multi-year collaboration to bring digital technologies to fertility treatments integrating informatics, mobile ultrasound diagnostics and more
  • The collaboration build on Philips’ expertise in maternal & fetal monitoring, Pregnancy+, Baby+ consumer engagement apps, which provide information on diet and exercise along with updates on the baby’s development
  • The companies will utilize remote patient monitoring, cloud-based platform services and mobile, AI-enabled ultrasound diagnostics to support improved access to care and better outcomes in fertility treatment

Click here ­to­ read full press release/ article | Ref: Philips | Image: Philips

The post Philips Collaborates with Merck KGaA to Advance Personalized Fertility Treatment first appeared on PharmaShots.

Abbott to Launch NeuroSphere myPath App to Record Pain Relief in Chronic Pain Patients

Shots:

  • The app will record pain relief during the device trial period with SCS or DRG therapy, simplifying reporting outcomes & connect patients to physicians who have real-time access to the data
  • The app will be compatible with Abbott’s Proclaim XR SCS system for patients living with chronic pain in the trunk & limbs and Proclaim DRG neurostimulation system for patients with chronic pain in the lower limbs
  • The app will allow patients to use their Apple phone to connect with Abbott support, access educational resources & track the progress of their trial pain relief journey. The app will be available on the Apple app store in the coming weeks and is expected to be available on android devices in Q2’21

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Chicago Tribune

The post Abbott to Launch NeuroSphere myPath App to Record Pain Relief in Chronic Pain Patients first appeared on PharmaShots.

Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

Shots:

  • The companies reported that joint Livongo for diabetes and dexcom members will now receive CGM-powered insights that enables members to easily visualize their health information and understand how lifestyle decisions affect their blood glucose levels
  • In Oct’2020, Teldoc merges with Livongo while in Jan’2020 Dexcom collaborated with Livongo to integrate Dexcom’s G6 CGM system into Livongo’s applied health signals platform
  • Both the companies will launch a pilot demonstrating the impact of CGM-powered insights for people with T2D, with a broader launch across 2021

Click here ­to­ read full press release/ article | Ref: Teladoc Health | Image: Teladoc Health

The post Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D first appeared on PharmaShots.

UCB Launches Nile AI as a Digital Health Company to Transform the Course of Epilepsy

Shots:

  • UCB invested $29.3M in Nile and as majority shareholder, will be the Board of Directors of Nile with future opportunities to acquire insights and data from Nile’s platform
  • Nile is developing a digital epilepsy care management platform and bringing together data to make the epilepsy journey predictable. The platform consists of patient app and HCP portal & is anticipated to be commercially available in 2021
  • Nile’s platform will serve as a digital extension of the HCPs with an aim of shortening the path to optimal treatment

Click here ­to­ read full press release/ article | Ref: UCB | Image: Pharmaphorum

The post UCB Launches Nile AI as a Digital Health Company to Transform the Course of Epilepsy first appeared on PharmaShots.

Biogen and Apple Collaborate to Launch Virtual Study on Cognitive Decline

Shots:

  • Biogen and Apple collaborated to evaluate the role of Apple Watch and iPhone in monitoring cognitive performance and screening for the decline in cognitive health including mild cognitive impairment (MCI)
  • The study will initiate in late 2021 and will enroll participants including young and aging adults with a range of cognitive performance
  • The study focuses to identify digital biomarkers to aid monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as AD

Click here ­to­ read full press release/ article | Ref: Biogen | Image: MyHealthyApp

The post Biogen and Apple Collaborate to Launch Virtual Study on Cognitive Decline first appeared on PharmaShots.

Google Launches Health Research App Focusing on Respiratory Illnesses

Shots:

  • Google has launched the Google Health Studies app for Android phones with the initial focus on respiratory diseases such as COVID-19. The app is now available in the play store
  • Google allied with researchers from Harvard Medical School and Boston Children Hospital for the first study, which will be open to adults in the US and will focus on identifying how these types of illnesses evolve in communities and differ across risk factors such as age, and activities
  • The app provides a platform for researchers to reach a large & diverse population to better understand human health while providing the public with greater opportunities to contribute to medical research

Click here to­ read the full press release/ article | Ref: Google | Image: Google

The post Google Launches Health Research App Focusing on Respiratory Illnesses first appeared on PharmaShots.

Elsevier Acquires Shadow Health

Shots:

  • Elsevier acquires Shadow Health to enhance its extensive portfolio and clinical practice offerings for HCPs during a time of continued growth in telehealth
  • Elsevier works with healthcare educators to prepare students, nursing and HCPs and provide innovative learning tools and analytics that improve educational outcomes and help prepare students for healthcare practice
  •  The acquisition follows the launch of Transition to Practice in the US, supporting new nurses to build skills & confidence as they transition from academia to professional clinical practice

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Transtutors

The post Elsevier Acquires Shadow Health first appeared on PharmaShots.

RetinAI Collaborates with Novartis to Provide AI Solutions in Ophthalmology

Shots:

  • RetinAI signs a multi-year collaboration with Novartis under which RetinAI’s IT solutions and AI tools will be employed to support multiple projects in ophthalmology and digital health
  • The first project under the agreement will support a multi-center international clinical study involving patients with nAMD. The study is designed to investigate the influence of OCT image solutions using AI on the assessment of disease activity
  • The study will be conducted across multiple centers in numerous EU countries and Canada, involving 500+ patients. RetinaAI will provide its data management platform to efficiently process data at scale across imaging platforms and devices

Click here ­to­ read full press release/ article | Ref: RetinAI | Image: Switzerland Global Enterprise

The post RetinAI Collaborates with Novartis to Provide AI Solutions in Ophthalmology first appeared on PharmaShots.

Exactech Acquires Muvr and it’s Digital Health Tech for Orthopedic Practices

Shots:

  • Exactech has acquired intelligent patient wearables and digital communication solutions maker Muvr Labs to expand its Active Intelligence platform of smart technologies portfolio
  • The Muvr platform includes patient wearables, mobile device applications, and chatbot texting, allowing the surgeons to remotely monitor patient recovery
  • Exactech expects a pilot launch of the Muvr technology in early 2021, with a full release of the platform by the end of 2021. Additionally, the company plans to develop the technology to support shoulder and ankle replacement surgery

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

The post Exactech Acquires Muvr and it’s Digital Health Tech for Orthopedic Practices first appeared on PharmaShots.

Kaia Health Allied with Chiesi Group to Commercialize COPD App in Europe

Shots:

  • Kaia Health signs an exclusive agreement with Chiesi Group to commercialize the Kaia Health COPD Pulmonary Rehabilitation app in the EU
  • The app is CE marked in EU as a Class 1 medical device and has been investigated in one pilot trial and is the subject of an ongoing randomized control trial in the EU
  • The Kaia COPD solution consists of a mobile app and an interface for motivational support that aims to deliver a personalized pulmonary rehabilitation experience through education, daily training sessions, and stress relief exercises, boosted with human coaching support and individualized therapy

Click here ­to­ read full press release/ article | Ref: Kaia Health | Image: Venture Beat

The post Kaia Health Allied with Chiesi Group to Commercialize COPD App in Europe first appeared on PharmaShots.

Bayer to Fund Five New Startup Companies as Part of G4A Digital Health Partnerships Program

Shots:

  • The funding focuses on fostering the development of a digital health ecosystem in the fields of cardiometabolic and renal diseases, oncology, and women’s health
  • Bayer G4A partnership program offers 2 digital health collaboration segments. Under its Growth Track, selected early-stage startups receive $118.29M funding to accelerate market uptake and tailored business acceleration clinics and through the Advance Track framework, digital health companies are aligning for larger commercial deals
  • Selected Growth Track partners include Caria and Elly Health while Selected Advance Track partners include Decipher Biosciences, Sweetch, and MyONCARE

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Bayer

Related News : Bayer’s G4A Digital Health Partnerships Program Signs an Agreement with Eleven Digital Health Startups Transforming Digital Health Solutions

The post Bayer to Fund Five New Startup Companies as Part of G4A Digital Health Partnerships Program first appeared on PharmaShots.

Pear Therapeutics Launches Somryst Insomnia App Via an End-to-End Virtual Care Experience

Shots:

  • Pear Therapeutics launches Somryst as the first PDT intended for use in the treatment of patients with chronic insomnia aged > 22yrs. It addresses the issues of chronic insomnia by delivering (CBTi) approach that trains the brain and body to sleep
  • In a study of ~1,400 adults with CI, PDT reduced the amount of time it took to fall asleep (45%), reduced the amount of time spent awake at night (52%) and reduced severity of insomnia symptoms (45%) with continued improvement at 6 & 12 mos. post-treatment
  • Somryst will be promoted via a fully virtual experience, combining telemedicine visits and PDT prescribing and dispensation via PearConnect

Click here ­to­ read full press release/ article | Ref: Pear therapeutics | Image: MobileHealthNews

The post Pear Therapeutics Launches Somryst Insomnia App Via an End-to-End Virtual Care Experience first appeared on PharmaShots.

Health2Sync Divulges Benefits of Integrating Fitbit Wearable Devices into Diabetes Care in Taiwan

Shots:

  • Health2Sync reported the results of their clinical study in Taiwan, demonstrating that integrating Fitbit wearable devices with their Health2Sync patient management platform can help users to control T2DM
  • Results: reduction in HbA1C (0.33%); patients who did mod. to high-intensity activity duration of at least 150mins/ week, reduction in HbA1C (0.66%); reduction in fasting BG (10.92 mg/dL), reduction in LDL-C (11.55 mg/dL); reduction of weight up to 2kg; increased frequency in mod. to high-intensity activity to 7.03 times a week among some patients
  • The Health2Sync’s platform allows HCPs to seamlessly monitor patients’ information and provide remote consultative advice where necessary

Click here­ to­ read full press release/ article | Ref: PRNewswire | Image: Harvey Norman

The post Health2Sync Divulges Benefits of Integrating Fitbit Wearable Devices into Diabetes Care in Taiwan first appeared on PharmaShots.

NightWare Receives the US FDA’s Approval for the First Medical Device to Stop NightMAres Related to PTSD

Shots:

  • The US FDA has permitted marketing of a device intended for the temporary reduction of sleep disturbance related to nightmares in patients aged ≥22 yrs. suffering from nightmare disorder or PTSD
  • Nightware utilizes Apple Watch and an iPhone that is configured and logged into a software application and the Nightware server and monitors the wearer’s HR and movement while they sleep and if they are having a nightmare, gently arouse them out of the dream without waking up completely, using the smartwatch’s vibrations
  • The platform received the US FDA’s BT designation in May’2019 and now is available by prescription only and is intended for home use

Click here ­to­ read full press release/ article | Ref: FDA | Image: IT PRO

The post NightWare Receives the US FDA’s Approval for the First Medical Device to Stop NightMAres Related to PTSD first appeared on PharmaShots.

Merck KGaA Collaborates with Iktos to Deploy AI in New Drug Design

Shots:

  • Iktos will leverage its de novo generative design technology to be used in a structure-enabled context, facilitating the rapid & cost-effective design of Merck KGaA’s drug discovery program
  • The collaboration follows the previous agreement of the companies signed in 2019. Merck KGaA is utilizing Iktos’ de novo design software platform Makya for MPO
  • Iktos’ AI technology is based on deep generative models that help bring speed & efficiency to the drug discovery process by automatically designing virtual novel molecules having desired activities for treating a disease

Click here to­ read the full press release/ article | Ref: Businesswire | Image: CIO.com

The post Merck KGaA Collaborates with Iktos to Deploy AI in New Drug Design first appeared on PharmaShots.

Eisai and Cogstate Expand their Agreement to Develop and Commercialize Digital Cognitive Assessment Technologies

Shots:

  • Eisai gets the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the CBB for use in healthcare and other markets. The agreement allows the two companies to replicate the advancements that have already been launched in Japan, where Eisai has developed and launched a new digital tool using the CBB, named NouKNOW
  • The collaboration is an expansion of an existing agreement signed in 2019, under which Eisai had exclusive development and commercialization rights in Japan for all cognitive function tests including CBB
  • Eisai and Cogstate will work together for the development of digital tools for simpler self-checks of cognitive function and diagnostic tool development for HCPs to promote greater awareness of brain performance globally

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BioSpectrum Asia

The post Eisai and Cogstate Expand their Agreement to Develop and Commercialize Digital Cognitive Assessment Technologies first appeared on PharmaShots.

AWS and Onica Collaborate with Teva to Support its Digihaler Portfolio

Shots:

  • The three companies collaborated to build & host Teva’s Digital Health Platform which is a cloud-based backend data system, supporting the company’s FDA-approved Digihaler portfolio that consists of built-in sensors and Bluetooth wireless technology which connects to a mobile app that tracks inhaler events and measures inspiratory flow when a patient inhales
  • Onica supported the serverless build of Teva’s platform and allow the system to deploy cloud capabilities of AWS. The digital health platform on AWS will allow for extreme scalability, resiliency, and cost-effectiveness
  • The cloud system allows user to view stored information on their Digihaler events via the companion mobile app, which can be linked to multiple inhaler devices

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Which-50

The post AWS and Onica Collaborate with Teva to Support its Digihaler Portfolio first appeared on PharmaShots.

Bayer and 111 Collaborate to Explore the Vast Blue Ocean of Online Healthcare in China

Shots:

  • The companies will collaborate on drug commercialization initiatives in China, including the commercialization of innovative drugs & healthcare products for chronic disease management, as well as providing reliable and convenient resources for patient education
  • Bayer will leverage 111’s vast network of pharmacies and healthcare providers to enhance its channel management and patient outreach capabilities, as well as to increase its market presence in several underserved markets in China’s tier 3-6 cities
  • The companies will jointly develop a digitalized content portal that will provide online pharmacist training and interactive patient education content and services

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Silver Peak Blog

The post Bayer and 111 Collaborate to Explore the Vast Blue Ocean of Online Healthcare in China first appeared on PharmaShots.

Takeda Collaborates with Accenture and AWS to Transform into a Cloud-Based Company

Shots:

  • Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the company in moving 80% of its applications to the cloud and modernizing its research tools
  • The transition of Takeda’s applications to the cloud will enable the company to remove non-differentiating technology and create a scalable architecture. The collaboration will leverage cloud and data-driven insights to accelerate drug development, increase operational agility, reduce technology costs, and develop the workforce of the future
  • Additionally, the collaboration with Accenture and AWS has already helped the Takeda to use the cloud in launching a clinical trial acceleration and secure data-sharing platform for the COVID R&D Alliance in <5days. The COVID R&D Alliance is a consortium comprising 20 companies, including Takeda, Amgen, and AbbVie to study and identify the potential of COVID-19 therapies

    Click here to­ read the full press release/ article | Ref: Takeda | Image: Enterprise Talk

The post Takeda Collaborates with Accenture and AWS to Transform into a Cloud-Based Company first appeared on PharmaShots.

GSK and AstraZeneca Plan to Deploy NVIDIA’s Supercomputer for Drug Development

Shots:

  • NVIDIA reports that it is building the “Cambridge-1” supercomputer, which will be an NVIDIA DGX SuperPOD system capable of delivering 400+ petaflops of AI performance and 8 petaflops of Linpack performance and 1s expected to come online by the end of 2020
  • GSK and AstraZeneca will be the first company to harness Cambridge-1 for research. Additionally, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, and Oxford Nanopore Technologies also plan to take advantage of the system
  • Cambridge-1 will be the first NVIDIA supercomputer designed and built for external research access and will provide researchers and academics the ability to tackle challenging AI training, inference, and data science workloads at scale. NVIDIA will invest ~ $51.7M in Cambridge-1

Click here ­to­ read full press release/ article | Ref: NVIDIA | Image: Medsmart App

The post GSK and AstraZeneca Plan to Deploy NVIDIA’s Supercomputer for Drug Development first appeared on PharmaShots.

Amazon Enters into Fitness Space with the Launch of Halo Band and App

Shots:

  • Amazon launches the Halo fitness band and a subscription service by the same name. The smart band combines a suite of AI-powered health tool with an innovative and stylish wrist band
  • Halo band and subscription service unlock an array of health metrics, including activity, sleep, body fat, and tone of voice analysis, to determine how you sound to others. Additionally, the band does not have screen unlike other smart bands
  • The Halo Band will cost $99.99 and the service costs $3.99/mos. The company is launching its early access program with the special price of $64.99 that includes 6mos.of the free service

Click here ­to­ read full press release/ article | Ref: Amazon | Image: Business Wire

Bayer and One Drop Collaborate to Develop Digital Therapies Across Multiple Therapeutic Areas

Shots:

  • The two partners will jointly enhance the existing platform utilizing One Drop’s know-how and capabilities of the One Drop platform and will co-develop digital health therapies across multiple therapeutic areas               
  • One Drop will receive $98M financing, development fees and commercial milestones while in exchange Bayer will receive royalties on sales. In the future, Bayer may also support the commercialization of the jointly developed digital products
  • The collaboration allows Bayer to accelerate its evolution towards a digital health business with a focus to provide integrated care patient service offerings

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Getty Images

BioSymetrics Signs an Agreement with Janssen and Sema4 to Utilize AI for the Prediction of COVID-19

Shots:

  • The companies will use BioSymetrics Contingent-AI engine to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course and identify markers for clinical phenotype and severity of the disease
  • The focus of the collaboration to predict the onset and severity of COVID-19 among different populations using machine learning
  • The collaboration will operate across several projects with a goal of enabling a vaccine and course of treatment against COVID-19

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Northeast Now

AstraZeneca Collaborates with Eko to Advance the Digital Health Tools for the Diagnosis of CV Diseases

Shots:

  • The two companies collaborated to facilitate the development of digital health tools for the earlier screening of cardiovascular diseases, including HF
  • AstraZeneca and Eko will accelerate the development of Eko algorithms, enhancing clinical trials with Eko technology, and potentially building new HF detection solutions. The agreement allows the companies to harness the potential to improve access to individualized care and generate better patient outcomes
  • In Dec’2019, Eko has received the US FDA’s BT designation for a novel ECG-based algorithm that can identify reduced LVEF. If approved, the algorithm will be compatible with the DUO, Eko’s handheld stethoscope, and ECG device

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Physician Practice




Baxter and Ayogo Expand their Partnership to Advance Digital Health Solution for Home Dialysis

Shots:

  • The companies expanded the collaboration to support the needs of patients with kidney disease via digital health solutions. The agreement integrates Ayogo’s LifePlan digital platform with Baxter’s expertise in renal care to develop mobile apps and digital solutions that bring personalized and timely support to patients with kidney failure
  • Baxter made an equity investment in Ayogo in exchange for a minority interest in the company. The new initiative will provide patients the ability to proactively manage their home dialysis therapy records in collaboration with their healthcare team
  • Earlier, the two companies collaborated to develop a patient engagement app, CKD&Me that provides customized disease and therapy education for the learning needs of patients with CKD. The companies have launched the app in the US and are preparing to expand it globally

Click here ­to­ read full press release/ article | Ref: Baxter | Image: StraitTimes




Abbott’s IOS-Compatible App Receives the US FDA’s Approval for Patients with Neurological Disorder

Shots:

  • The US FDA approves Abbott’s patient controller app for use on Apple’s smartphone devices, allowing patients with neurological conditions such as chronic pain or movement disorders to manage their therapy directly from their smartphone
  • The company plans to integrate the app into Abbott’s NeuroSphere Digital Care, launched in May’2020 which is compatible with Infinity DBS System for patients with PD or essential tremor, Proclaim XR SCS system and Proclaim DRG Neurostimulation system for patients with chronic pain and chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia respectively
  • The integration across all Abbott neuromodulation technologies allows physicians to treat patients more easily within their practice who have an Abbott device and Apple smartphone. The patient controller app with personalized access to therapy will be available imminently

Click here to read full press release/ article | Ref: Abbott | Image: Twaku




Chugai and Biofourmis Collaborate to Develop Solutions for Digitally Measuring Endometriosis Pain

Shots:

  • The collaboration will deploy Biofourmis’ Biovitals platform to co-develop a novel digital technology for the objective assessment of pain using biosensors and AI-based algorithms. The solutions will be validated in the global study that enrolls 120+ endometriosis patients
  • The digital solution for managing patients with endometriosis in an ambulatory setting will include a wearable, clinical-grade biosensor to capture physiology biomarkers and a mobile app to monitor symptoms, with a gamification engine for patient engagement
  • The technology applies analytics to physiology biomarkers for quantification of pain and will include a clinician-facing web dashboard for remote review and intervention.  Chugai is demonstrating its commitment to applying the advanced digital technologies for better understanding the real-life needs of patients and to develop innovative solutions for society, as outlined in the CHUGAI DIGITAL VISION 2030

Click here to read full press release/ article | Ref: PRNewswire | Image: Biofourmis




Biocon Collaborates with Voluntis on Digital Therapeutics for Insulins

Shots:

  • The two companies collaborated to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The collaboration allows Biocon to offer Insulia to T2D patients across several markets globally
  • Biocon aspires to reimagine the patient ecosystem by developing a technology-dependent operating model enabling personalization of care, thus going beyond the product to reduce both the cost of the drug as well as the cost of administering the drug
  • Insulia is the US FDA cleared and CE-marked digital therapeutic with regulatory clearance to provide automated titration recommendations for all types of basal insulins. Biocon is extending the Insulia platform to its complete range of insulin products, including Recombinant Human Insulin, Insulin Glargine and Insulin Aspart, creating a digital therapeutics portfolio for patients

Click here to read full press release/ article | Ref: Biocon | Image: Twitter